trial · primary record
Sacituzumab tirumotecan
Metastatic Castration-resistant Prostate Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 290 |
| Primary completion | 2032-06-29 |
| Primary endpoint | Efficacy Phase: Objective Response Rate (ORR) |
| Registry ID | NCT07908524 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:38.660Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07908524
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Sacituzumab tirumotecan · compound